The evaluation of drotaverin intake during pregnancy on fetal development

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The safety of drotaverin use during pregnancy is not yet proven, thus the objective of the study was the evaluation of this drug for its effect on fetal development. Method: The dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1991, was analyzed. Results: During the study period, 9.5% of 30 663 pregnant women who had healthy babies (negative control group), 9.4% of 17 300 pregnant women who had babies with congenital abnormalities (index patient group), and 8.0% of 667 pregnant women who had babies with Down's syndrome (positive control group), were treated with drotaverin. The main reasons for drotaverin use were threatened abortion during the second or third month and threatened preterm delivery in the last months of pregnancy. The analysis of index patient-matched control pairs did not show a higher use of drotaverin treatment among mothers of index patients with different congenital abnormality groups. The use of drotaverin was significantly lower in the group of cleft palate. Conclusion: The use of drotaverin had no detectable teratogenic effect.

Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalPrenatal and Neonatal Medicine
Volume1
Issue number2
Publication statusPublished - 1996

Fingerprint

Fetal Development
Pregnancy
Pregnant Women
Threatened Abortion
Control Groups
Drug Evaluation
Cleft Palate
Down Syndrome
drotaverin
Mothers
Safety

Keywords

  • Case-control method
  • Cleft palate
  • Congenital abnormality monitoring/surveillance
  • Drotaverin
  • Teratogenic effect

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The evaluation of drotaverin intake during pregnancy on fetal development. / Czeizel, E.; Rockenbauer, M.

In: Prenatal and Neonatal Medicine, Vol. 1, No. 2, 1996, p. 137-145.

Research output: Contribution to journalArticle

@article{966f8efa95a2409ca3b3a54d972b6aaf,
title = "The evaluation of drotaverin intake during pregnancy on fetal development",
abstract = "Objective: The safety of drotaverin use during pregnancy is not yet proven, thus the objective of the study was the evaluation of this drug for its effect on fetal development. Method: The dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1991, was analyzed. Results: During the study period, 9.5{\%} of 30 663 pregnant women who had healthy babies (negative control group), 9.4{\%} of 17 300 pregnant women who had babies with congenital abnormalities (index patient group), and 8.0{\%} of 667 pregnant women who had babies with Down's syndrome (positive control group), were treated with drotaverin. The main reasons for drotaverin use were threatened abortion during the second or third month and threatened preterm delivery in the last months of pregnancy. The analysis of index patient-matched control pairs did not show a higher use of drotaverin treatment among mothers of index patients with different congenital abnormality groups. The use of drotaverin was significantly lower in the group of cleft palate. Conclusion: The use of drotaverin had no detectable teratogenic effect.",
keywords = "Case-control method, Cleft palate, Congenital abnormality monitoring/surveillance, Drotaverin, Teratogenic effect",
author = "E. Czeizel and M. Rockenbauer",
year = "1996",
language = "English",
volume = "1",
pages = "137--145",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - The evaluation of drotaverin intake during pregnancy on fetal development

AU - Czeizel, E.

AU - Rockenbauer, M.

PY - 1996

Y1 - 1996

N2 - Objective: The safety of drotaverin use during pregnancy is not yet proven, thus the objective of the study was the evaluation of this drug for its effect on fetal development. Method: The dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1991, was analyzed. Results: During the study period, 9.5% of 30 663 pregnant women who had healthy babies (negative control group), 9.4% of 17 300 pregnant women who had babies with congenital abnormalities (index patient group), and 8.0% of 667 pregnant women who had babies with Down's syndrome (positive control group), were treated with drotaverin. The main reasons for drotaverin use were threatened abortion during the second or third month and threatened preterm delivery in the last months of pregnancy. The analysis of index patient-matched control pairs did not show a higher use of drotaverin treatment among mothers of index patients with different congenital abnormality groups. The use of drotaverin was significantly lower in the group of cleft palate. Conclusion: The use of drotaverin had no detectable teratogenic effect.

AB - Objective: The safety of drotaverin use during pregnancy is not yet proven, thus the objective of the study was the evaluation of this drug for its effect on fetal development. Method: The dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1991, was analyzed. Results: During the study period, 9.5% of 30 663 pregnant women who had healthy babies (negative control group), 9.4% of 17 300 pregnant women who had babies with congenital abnormalities (index patient group), and 8.0% of 667 pregnant women who had babies with Down's syndrome (positive control group), were treated with drotaverin. The main reasons for drotaverin use were threatened abortion during the second or third month and threatened preterm delivery in the last months of pregnancy. The analysis of index patient-matched control pairs did not show a higher use of drotaverin treatment among mothers of index patients with different congenital abnormality groups. The use of drotaverin was significantly lower in the group of cleft palate. Conclusion: The use of drotaverin had no detectable teratogenic effect.

KW - Case-control method

KW - Cleft palate

KW - Congenital abnormality monitoring/surveillance

KW - Drotaverin

KW - Teratogenic effect

UR - http://www.scopus.com/inward/record.url?scp=1542500880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542500880&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:1542500880

VL - 1

SP - 137

EP - 145

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 2

ER -